Affiliations 

  • 1 Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China
  • 2 Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China. liud@wh.iov.cn
Virol Sin, 2018 Oct;33(5):385-393.
PMID: 30311101 DOI: 10.1007/s12250-018-0050-1

Abstract

Nipah virus (NiV), a zoonotic paramyxovirus belonging to the genus Henipavirus, is classified as a Biosafety Level-4 pathogen based on its high pathogenicity in humans and the lack of available vaccines or therapeutics. Since its initial emergence in 1998 in Malaysia, this virus has become a great threat to domestic animals and humans. Sporadic outbreaks and person-to-person transmission over the past two decades have resulted in hundreds of human fatalities. Epidemiological surveys have shown that NiV is distributed in Asia, Africa, and the South Pacific Ocean, and is transmitted by its natural reservoir, Pteropid bats. Numerous efforts have been made to analyze viral protein function and structure to develop feasible strategies for drug design. Increasing surveillance and preventative measures for the viral infectious disease are urgently needed.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.